COSCIENS Biopharma Inc.

TORONTO, ONTARIO, Sept. 16, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“) is pleased to announce, further to the press release dated September 10, 2026, the closing of the second tranche of a non-brokered private placement of the 15% unsecured convertible debentures (the “Offering“). In the second tranche of the Offering, the Company issued additional unsecured convertible debentures (the “Debentures“) in an aggregate principal amount of US$4,375,000 million, for an aggregate principal amount, together with the first closing, of US$10,706,250. The terms of the Offering contemplate the issuance of an aggregate principal amount of Debentures up to US$20 million, and the Company anticipates closing one or more additional tranches in the coming weeks. Completion of additional tranches is subject to customary closing conditions, and there can be no assurance that additional tranches will be completed. As previously disclosed, pursuant to the rules and policies of the Toronto Stock Exchange (the “TSX“), the conversion rights and certain related terms of the Debentures require shareholder approval. The Company has agreed to call a meeting of shareholders (the “Meeting“) within six months to seek the necessary approvals. Additional details will be provided in a forthcoming management […]

TORONTO, ONTARIO, Sept. 10, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“) is pleased to announce the acquisition of Nualtis Corp. (“Nualtis“), a Montreal-based specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies, with applications for both human and animal health. The Company also announced the completion of the first tranche of a non-brokered private placement of unsecured convertible debentures. ACQUISITION HIGHLIGHTS: Strategic acquisition of a leading oral thin film (“OTF”) development and manufacturing platform: Nualtis is an industry leader and innovator in OTF drug delivery technology, adding a purpose-driven team and an FDA- and Health Canada-inspected GMP manufacturing facility in Montreal, Canada. Established development and commercial partnerships across a diversified product pipeline: A portfolio of programs spanning human and animal health, protected by 21 foundational patents, with partnerships in place with established pharmaceutical companies. Growing cash-flow-positive business model: The Company believes Nualtis is poised for continued, profitable future growth through diverse revenue streams, including research and development (“R&D“) services, manufacturing and supply, milestone payments, and product royalties. “We are very excited to announce the acquisition of Nualtis. COSCIENS now has direct exposure to the large and growing global […]

TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“COSCIENS” or the “Company“) today reported its financial and operating results for the second quarter ended June 30, 2026. All amounts in this press release are in U.S. dollars. Q2 2026 and YTD Financial Highlights $5.3 million in cash and cash equivalents at June 30, 2026. Consolidated net loss for Q2 2026 of $0.2 million or $0.19 net loss per common share, as compared with a consolidated net loss of $2.7 million, or $2.57 net loss per common share for Q2 2025. The $2.5 million decrease in net loss is primarily attributable to higher gross margins from increased sales volumes and production efficiencies, lower selling, general and administrative expenses, and the reduction of losses from the discontinued operations of the Company’s German subsidiary, AEZS Germany. Consolidated net income for the first half of 2026 of $10.6 million or $10.08 net income per common share, as compared with a consolidated net loss of $6.4 million, or $6.05 net loss per common share for the same period in 2025. The $17.0 million increase in net income is primarily attributable to the $10.9 million of income from discontinued […]

TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“), today announced the previously announced consolidation (the “Consolidation“) of the common shares of the Company (the “Common Shares“) on the basis of a ratio of one post-Consolidation Common Share for every 150 pre-Consolidation Common Shares (the “Consolidation Ratio“); and (ii) an immediate subsequent split (the “Split“) of the Common Shares on the basis of 50 Common Shares for every one post-Consolidation Common Share (collectively, the “Share Capital Amendment“), became effective today (the “Effective Date“). Shareholders who held fewer than 150 Common Shares as of the close of business yesterday became entitled to a cash payment of US$1.60 in exchange for their pre-Consolidation Common Shares. All other shareholders participated in the Split and, as a result, will have their pre-Consolidation interest reduced by a factor of three (subject to rounding any post-Split fractional interests). The Common Shares are expected to begin trading on a post-Share Capital Amendment basis on the TSX within two business days of the Effective Date under the same trading symbol. As previously announced, letters of transmittal were mailed to registered shareholders on or about May 26, 2026 providing […]

TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“) announced the next steps in connection with changes to the Company’s share capital (the “Share Capital Amendment“). The Share Capital Amendment was approved at the Company’s annual general and special meeting of shareholders held on June 17, 2026. The Share Capital Amendment consists of (i) a consolidation (the “Consolidation“) of the Company’s common shares (“Common Shares“) on the basis of one post-Consolidation Common Share for every 150 pre-Consolidation Common Shares; and (ii) an immediate subsequent split (the “Split“) of the Common Shares on the basis of 50 Common Shares for every one post-Consolidation Common Share. The Share Capital Amendment is expected to become effective on July 3, 2026 (the “Effective Date“) for Common Shares held by shareholders as of such time, and the Common Shares are expected to begin trading on the Toronto Stock Exchange on a post-Share Capital Amendment basis within two business days of the Effective Date under the same trading symbol. As described in the management information circular dated May 18, 2026 (the “Circular“), shareholders with positions representing fewer than 150 Common Shares as of the Effective Date […]

TORONTO, ONTARIO, June 18, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“) announced the results from its annual general and special meeting of shareholders (the “Meeting“). At the Meeting, all matters put to shareholders for consideration and approval, as set out in the Company’s management proxy circular dated May 18, 2026 (the “Circular“), were approved by the requisite number of votes cast at the Meeting, including (1) the re-election of all director nominees, (2) the re-appointment of Deloitte LLP as auditors, and (3) the authorization to proceed with the changes in the Company’s share capital the (“Share Capital Amendment“), consisting of (i) the consolidation (the “Consolidation“) of the Company’s common shares (“Common Shares“) on the basis of one post-Consolidation Common Share for every 150 pre-Consolidation Common Shares (the “Consolidation Ratio“); and (ii) the immediate subsequent split (the “Split“) of the Common Shares on the basis of 50 Common Shares for every one post-Consolidation Common Share. The complete voting results of all matters voted on at the Meeting are available on SEDAR+ under the Company’s issuer profile at www.sedarplus.ca. The Company will provide further information with respect to the proposed Share Capital Amendment in […]

TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“) today reported its financial and operating results for the first quarter ended March 31, 2026. All amounts in this press release are in U.S. dollars. Q1 2026 Financial Highlights $5.0 million in cash and cash equivalents at March 31, 2026. Consolidated net income of $10.8 million or $3.42 net income per common share, as compared with a consolidated net loss of $3.7 million, or $1.16 loss per common share for Q1 2025. The $14.4 million increase in net income is primarily attributable to the $10.9 million of Income from discontinued operations recognized upon the deconsolidation of the Company’s German subsidiaries from the consolidated financial results (as further discussed below). Consolidated net loss from continuing operations of $0.2 million or $0.06 net loss per common share as compared to consolidated net loss from continuing operations of $2.7 million or $0.85 net loss per common share for Q1 2025. The $2.5 million decrease reflects a decrease in total operating expenses of $1.5 million, an increase in other income of $0.6 million, and increase in gross margin of $0.4 million. Total revenue of $1.9 […]

TORONTO, ONTARIO, April 20, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“) announced today that it has filed a Rule 13e-3 Transaction Statement (the “Transaction Statement“) with the U.S. Securities and Exchange Commission (the “SEC“). As previously disclosed, as part of its overall cost savings initiative, the Company voluntarily delisted from the Nasdaq Capital Market effective September 5, 2025, as the first step in a broader strategy to seek to terminate or suspend its public reporting obligations under the U.S. Securities Exchange Act of 1934 (the “Exchange Act“). The Transaction Statement describes the Company’s proposal to, subject to the receipt of necessary regulatory and shareholder approvals, undertake a two-step transaction consisting of (i) a consolidation (the “Consolidation“) of the Company’s common shares on the basis of a one post-Consolidation common share for every 150 pre-Consolidation common shares, and (ii) an immediately subsequent share split of the common shares on the basis of 50 common shares for every one (1) post-Consolidation common share (the “Split“, and together with the Consolidation, the “Share Capital Amendment“). Pursuant to the proposed Share Capital Amendment: (i) shareholders holding fewer than 150 pre-Consolidation common shares at the effective time, […]

TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“) is issuing this news release in response to unusual market activity. While the Company does not normally comment on market activity or market speculation, the Company confirms that it is not aware of any material undisclosed information relating to the Company that would account for the recent increase in trading activity in, and trading price of, the Company’s common shares. About COSCIENS Biopharma Inc. COSCIENS is a life science company focused on the development of natural, plant-based active ingredients, leveraging the Company’s proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide. The Company’s common shares are listed on the TSX under the symbol “CSCI” and are listed and posted for trading on the OTCQB® Venture Market under the symbol “CSCIF”. For more information, please visit COSCIENS’ website at www.cosciensbio.com. Issuer Contact:Peter H. Puccetti Interim CEO and Chairman of the Boardpp@cosciensbio.com Giuliano La FrattaChief Financial Officerglafratta@cosciensbio.com Investor Contact:IR@cosciensbio.com

TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company“), a life science company focused on the development of natural, plant-based active ingredients, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. All amounts in this press release are in U.S. dollars. Corporate Update Following the reconstitution of the Company’s board of directors (the “Board“) on May 30, 2025, the Company has undertaken a series of initiatives designed to follow through on the commitment of the reconstituted Board to actively review COSCIENS’ prospects and opportunities, and to take the actions necessary to best position COSCIENS to create value for shareholders. Notably, during the second half of 2025, the Company executed a comprehensive restructuring plan designed to streamline operations and enhance efficiency. Through this restructuring, combined with disciplined cost management and targeted cost reduction initiatives, the Company has meaningfully reduced its burn rate and right sized the organization to better align with current market conditions and growth opportunities. More recently, on March 5, 2026, the Company announced that it had made the strategic decision to cease funding its German subsidiaries, through which it […]